Alternaria Alternata (Alt a 1) IgE Test · Blood

If your asthma flares in late summer, your nose runs every fall, or your symptoms get worse in damp homes, Alternaria mold is one of the most likely culprits. This test pinpoints whether your immune system has built a specific reaction to Alt a 1, the dominant protein that defines a true Alternaria allergy.

Knowing this changes what you do next. A confirmed Alt a 1 sensitization can explain stubborn rhinitis or wheezing, guide targeted treatment including allergen immunotherapy, and separate a real fungal trigger from a generic high reading on a broad mold panel.

What This Test Actually Measures

Alt a 1 (Alternaria alternata allergen 1) is a small protein found mainly in the spore wall of Alternaria mold, a fungus that grows on plants, soil, and damp indoor surfaces. The test does not measure mold in your body. It measures Alt a 1 sIgE (specific immunoglobulin E), the antibodies your immune system has produced against that single mold protein.

Specific IgE is the antibody class that drives allergic reactions. When your immune system has been primed to a substance, it makes IgE that locks onto that protein and triggers the release of histamine and other inflammatory signals on re-exposure. Measuring IgE to Alt a 1 in serum tells you, with high precision, whether your immune system treats Alternaria as an enemy.

This component-based testing is more precise than older whole-mold extract tests. Studies show that 80 to 98% of Alternaria-allergic patients carry IgE to Alt a 1, making it the single best marker to confirm a real Alternaria allergy rather than nonspecific or cross-reactive mold reactivity.

Why Alt a 1 Beats a Generic Mold Panel

Whole-mold extract tests mix many fungal components together, which means a positive result can reflect cross-reactivity with unrelated molds rather than a true Alternaria problem. Testing for the Alt a 1 component sharpens the picture and identifies the molecule actually driving your allergy.

In one study of adults with Alternaria allergy, 98% of patient samples bound Alt a 1, and Alt a 1 absorbed about 74% of the total IgE binding to whole Alternaria extract. In a pediatric cohort, IgE to Alternaria extract and IgE to Alt a 1 tracked each other very closely (correlation around 0.94), with Alt a 1 catching the vast majority of sensitized patients. Roughly 2% of Alternaria-sensitized patients react to other Alternaria proteins without Alt a 1, so component testing identifies the real Alternaria allergy in the strong majority of cases.

Alt a 1 is also recognized as a marker for a whole family of related molds called Pleosporaceae, including Ulocladium and Stemphylium. A positive Alt a 1 result therefore captures sensitization to several closely related outdoor molds at once.

Asthma and Allergic Airway Disease

Alt a 1 sensitization is most strongly linked to asthma and allergic rhinitis, especially in children and young adults. In a study of 582 asthmatic patients, those sensitized to Alternaria tended to be younger, more often male, and had higher total IgE, higher specific IgE levels, and broader polysensitization patterns consistent with type-2 (eosinophilic) asthma.

Sensitization to Alternaria is also tied to more reactive airways. In a study of asthmatic patients with positive Alternaria skin tests, a clear majority had a positive bronchial provocation test, confirming that the immune reaction translates into actual airway narrowing. In adults with high IgE and IgG to recombinant Alt a 1, the antibody profile clearly identified true Alternaria sensitization in asthma and rhinoconjunctivitis cases.

Allergic Rhinitis and Rhinoconjunctivitis

Patients with Alternaria-driven rhinitis or rhinoconjunctivitis show high rates of Alt a 1 sIgE. In studies using a multiplex platform called ALEX2 (Allergy Explorer 2), Alternaria and Alt a 1 sensitization were repeatedly tied to nasal and conjunctival symptoms. The clinical pattern is often seasonal, peaking when outdoor Alternaria spore counts rise in late summer and early fall.

In a Spanish cohort of 1,156 patients, Alternaria alternata and its major allergen Alt a 1 were the most common sources of fungal sensitization, showing how often Alt a 1 underlies seasonal mold-related upper-airway disease.

Chronic Rhinosinusitis with Nasal Polyps

Local Alt a 1 protein deposited in sinus tissue has been linked to recurrence of chronic rhinosinusitis with nasal polyps. In a study of 64 patients, higher tissue Alt a 1 levels were associated with more local Alternaria-specific IgE, more type-2 inflammation markers (IL-4, IL-33, and the eosinophil marker galectin-10), and a higher chance of polyp regrowth after surgery. Blood Alt a 1 sIgE does not directly measure tissue levels, but a strong systemic sensitization suggests sustained exposure that may keep feeding sinus inflammation.

Atopic Dermatitis: A More Nuanced Picture

In eczema, the story is less clean. Many atopic dermatitis patients show high IgE to whole Alternaria extract, but Alt a 1 IgE is often low or absent. This is one of the clearest examples of why component testing matters. A high extract IgE in an eczema patient often reflects nonspecific or cross-reactive binding, not a true Alternaria-driven skin problem.

If you have atopic dermatitis and broad mold reactivity on a standard panel, an Alt a 1 sIgE result helps separate genuine Alternaria sensitization from background atopic noise.

Tracking Your Trend

A single Alt a 1 sIgE reading tells you whether your immune system currently recognizes the protein. But the value of this number grows when you can see it move over time, especially if you start treatment.

In a randomized placebo-controlled trial of subcutaneous immunotherapy (SCIT) with Alt a 1, just one year of treatment cut symptoms and medication use and shifted antibody profiles. In a 24-month pilot in children, Alt a 1 sIgE fell from 28.6 to 19.5 kUA/L (kilounits of antibody per liter, a standard concentration unit for specific IgE), and additional studies have shown the same direction of change with rising protective IgG4 antibodies.

For someone managing mold-driven asthma or rhinitis, get a baseline test, retest in 6 to 12 months if you start immunotherapy or have major exposure changes, and at least annually thereafter. Trends matter more than a single number because a positive result still carries a wide range of clinical relevance, and meaningful changes from treatment typically take months to show up.

What to Do If Your Result Is Positive

A positive Alt a 1 sIgE confirms genuine Alternaria sensitization, but it does not by itself prove that Alternaria is the main cause of your symptoms. Match the result to your history. If your nasal, sinus, or asthma symptoms worsen in late summer, in damp buildings, or near agricultural areas, the result fits the clinical picture and should drive action.

Pair this test with whole Alternaria extract sIgE to catch the small fraction of patients sensitized to non-Alt a 1 components, and consider a broader component panel covering dust mites, pollens, pets, and other molds to identify all your triggers. Total IgE adds context, especially in asthma with very high atopic load. If your symptoms are significant and your Alt a 1 result is positive, an allergist or pulmonologist can decide whether bronchial or nasal provocation testing is needed before considering allergen-specific immunotherapy.

When Results Can Be Misleading

A few situations can blur the interpretation of a single Alt a 1 sIgE reading:

• Sensitization without disease: detecting IgE proves your immune system is primed, but not every primed person has active symptoms. Polysensitized patients may have multiple drivers competing for blame.
• Extract-only testing: a negative whole Alternaria extract test in someone with strong clinical suspicion does not always rule out a problem, and a positive extract test in eczema can overstate Alternaria's role.
• Recent immunotherapy: if you have been on Alternaria SCIT, your specific IgE pattern is intentionally being modulated, and changes over months reflect treatment rather than disease progression.
• Assay variation: different lab platforms (ImmunoCAP, ALEX2, ISAC) correlate well but can produce slightly different numerical values, so try to track trends on the same platform when possible.

Sensitization Versus Allergy

Keep a clear line between two ideas. Sensitization means your immune system has produced IgE to Alt a 1. Allergy means that IgE actually causes symptoms when you encounter the mold. Most sensitized people with relevant exposure do have symptoms, but the test alone confirms only the immune readiness. The clinical picture decides whether the result matters and what to do.